Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients  by Azazi, Ensaf A. et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2014) 63, 279–284The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLESerum levels of Interleukin-33 and its soluble receptor
ST2 in asthmatic patientsEnsaf A. Azazi b,1, Ashraf E. Elshora a,*, Enas A. Tantawy b,2, Marwa A. Elsayd b,3a Chest Department, Zagazig University, Faculty of Medicine, Egypt
b Microbiology and Immunology Department, Zagazig University, Faculty of Medicine, EgyptReceived 21 October 2013; accepted 10 November 2013
Available online 5 December 2013*
E-
ya
dr
1
2
3
Pe
D
04
OpKEYWORDS
Interleukin-33;
Soluble ST2;
Bronchial asthmaCorresponding author. Tel.:
mail addresses: ensafazazi@
hoo.com (A.E. Elshora), Ena
_vampier_zag@yahoo.com (
Tel.: +20 1223630643.
Tel.: +20 100837372.
Tel.: +20 1004214566.
er review under responsibil
iseases and Tuberculosis.
Production an
22-7638 ª 2013 The Egyptia
en access under CC BY-NC-ND li+20 122
yahoo.co
satantaw
M.A. Elsa
ity of Th
d hostin
n Society
httpcense.Abstract Interleukin-33 is a member of IL-1 family of cytokines and binds to two receptors: ST2
(IL-1-R1) and IL-1 receptor accessory protein (IL-1RAP). There are two isoforms of ST2 proteins:
ST2L, a transmembrane form, and a soluble ST2 (sST2), a secreted form, that can serve as a decoy
receptor of IL-33. The IL-33/ST2 signaling pathway activates airway eosinophils that exacerbate
airway inﬂammation.
The aim of this study was to analyze the serum level of IL-33 and its receptor sST2 in patients
with bronchial asthma to assess if the serum level of IL-33 and/or sST2 may be a marker of the dis-
ease severity and potential therapeutic targets.
Patients and methods: This study was carried out at the Microbiology & Immunology and Chest
departements, Faculty of Medicine, Zagazig University Hospitals during the period from December
2012 to September 2013. The study included 30 patients diagnosed as bronchial asthma according
to GINA 2012. Patients were classiﬁed into two groups: Group I: included 15 patients 8 males and 7
females with a mean age 36.2 ± 15.8 during exacerbation of bronchial asthma. Group 2: included
15 patients 8 male and 7 female with mean age 37.3 ± 12.8. They were stable asthmatic patients and
the last exacerbation was one month ago. There were 30 normal healthy persons as a control group.
All patients were subjected to, full medical history, general and local examination, Plain chest X-ray
PA and lateral views, pulmonary function tests, Liver and kidney function tests, intradermal skin
test, skin prick test, measurement of serum levels of IL-33 (WEKA MED), IL-33 Receptor (soluble3595477.
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280 E.A. Azazi et al.ST2) (OmniKine) and total IgE (IMMUNOSPEC) by enzyme linked immunosorbent technique
using commercial kits.
Results: There was a highly signiﬁcant increase in the serum level of IL-33 in both groups of
patients (p1 < 0.001) with the highest level 960 ± 336 ng/ml in group 1 followed by
732.2 ± 68.3 ng/ml in group 2 while the normal control group serum level was 174 ± 41 ng/ml.
As regards serum level of sST2, there was a highly signiﬁcant increase in its level in both groups
of patients (p1 < 0.001) with the highest level 96.8 ± 25 lg/ml in group 1 followed by
83.3 ± 5.3 lg/ml in group 2 while the normal control group serum level was 33.9 ± 9.6 lg/ml.
In acute exacerbated patients there was signiﬁcant ve correlation between FEV1 and serum level
of both total IgE and IL-33 and in stable asthmatic patients there was high signiﬁcant +ve corre-
lation between PEFR variability and serum level of sST2.
Conclusion: The serum levels of IL-33 and its receptor sST2 were markedly elevated in patients
with bronchial asthma and this supports the concept of sST2 and Interleukin-33 as a therapeutic
target in asthma.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Bronchial asthma is thought to be T helper 2 (Th2) cell-medi-
ated immune diseases. Th2 cells produce cytokines, such as
interleukin (IL)-33 which is also a chemoattractant for human
Th2 cells. IL-33 is produced by mast cells after immunoglobu-
lin (Ig) E-mediated activation and is able to trigger mast cells
to release proinﬂammatory cytokines in vitro [1]. IL-33 is a
member of the IL-1 family of cytokines and binds to two
receptors: ST2 (IL-1R1) and IL-1 receptor accessory protein
(IL-1RAP). There are two isoforms of ST2 proteins: ST2L, a
transmembrane form, and soluble ST2 (sST2), a secreted form
that can serve as a decoy receptor of IL-33. ST2 is highly
expressed on mast cells and selectively on Th2 cells [2].
High levels of sST2 have been found in the sera of adults
and children with acute asthma [3].
The IL-33/ST2 signaling pathway activates airway eosino-
phils that exacerbate airway inﬂammation. This pathway is
critical for the progression of IgE-dependent inﬂammation.
Mutations in the gene for IL1RL1 (ST2) have been linked to
atopic dermatitis and asthma [4]. Steroids and combination
therapies with long-acting b-agonists are the mainstay of asth-
ma treatment and effectively suppress cytokine expression and
acute inﬂammatory symptoms. However, they do not prevent,
reverse or treat the underlying causes of disease. These treat-
ments require constant monitoring and are associated with
side-effects and resistance. Therefore, there is an urgent need
for new and more effective treatments and cytokines have been
extensively investigated as potential therapeutic targets. So the
aim of this study was to analyze the serum level of IL-33 and
its receptor sST2 in patients with bronchial asthma to assess if
the serum level of IL-33 and/or sST2 may be a marker of the
disease severity and potential therapeutic targets.Patients and methods
This study was carried out at the Microbiology & Immunology
and Chest Departments, Faculty of Medicine, Zagazig Univer-
sity Hospitals during the period from November 2012 to
November 2013.The study included 30 patients with mean
age 36.7 ± 14.2 diagnosed as bronchial asthma according to
GINA 2012 [5] as follows:- Recurrent episodes ofwheezing, breathlessness, chest tightness,
and coughing, particularly at night or in the early morning.
- Pulmonary function test demonstrating reversible airway
obstruction, manifested by post bronchodilator increase
in FEV1 > 15%.
- Peak expiratory ﬂow (PEF): variability by 7–20%.Patients were classiﬁed to two groups:
 Group I (asthmatic patients during acute exacerbations):
This group included 15 patients; 8 males and 7 females with
a mean age 36.2 ± 15.8, during exacerbation of bronchial
asthma.
The severity of exacerbations was assessed according to
GINA (2012) [5], as mild, moderate, severe and respiratory
arrest imminent.
 Group 2 (stable asthmatic patients):
This group included 15 patients 8 males and 7 females with
mean age 37.3 ± 12.8. They were stable asthmatic patients and
the last exacerbation was one month ago. They were classiﬁed
according to GINA 2012 into: controlled, partially controlled
and uncontrolled.
 Control group:
There were 30 normal healthy persons as a control group
they were 15 males and 15 females with mean age 34.5 ± 9.
All patients were subjected to full medical history, general
and local examination, Plain chest X-ray PA and lateral views,
pulmonary function tests, Liver and kidney function tests and
eosinophilic count. Measurement of serum levels of IL-33,
sST2 and total IgE and commercial enzyme-linked immuno-
sorbent assays were used to measure serum levels of IL-33
(WKEA MED), sST2 (OmniKine) and total IgE (IMMUNO-
SPEC). The assays were performed using the protocols recom-
mended by the manufacturers.
Statistical analysis
Statistical analysis was performedwith SPSS version19 software
package (SPSS, Inc. Chicago). Categorical variables were
Table 1 Serum levels of IL33 in the studied groups.
IL33(ng/ml) Group 1 Group 2 Control F P1 P1
X± SD 960 ± 336 732.2 ± 68.3 174 ± 41.2 120.433 <0.001 0.001
Range 700–1700 600–860 130–250
X =mean.
P1: means probability of difference among the three groups.
P2: means probability of difference between group1 and group2.
Figure 1 Serum level of IL33 (ng/ml) in the studied groups. Figure 2 Serum level of sST2 (lg/ml) in the studied groups.
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were not normally distributedwere expressed asmeans ± SDor
medians (quartiles), respectively. The t-test or Mann–Whitney
test was used to compare means or medians between different
groups, for variables that were or were not normally distributed,
respectively. For all analyses, P value <0.05 was considered
signiﬁcant.
Results
Table 1 shows that there is a highly signiﬁcant difference
(p1 < 0.001) in serum levels of IL-33 among the three studied
groups with the highest level as 960 ± 336 ng/ml in group 1
(asthmatic patients during exacerbations) followed by
732.2 ± 68.3 ng/ml in group 2 (stable asthmatic patients) while
the normal control group serum level is 174 ± 41.2 ng/ml.
There is also a signiﬁcant difference (p1 = 0.001) between
group 1 and group 2 (Fig. 1).
Table 2 shows that there is a highly signiﬁcant difference
(p1 < 0.001) in serum levels of sST2 among the three studied
groups with the highest level as 96.8 ± 25 lg/ml in group 1
(asthmatic patients during exacerbations) followed by
83.3 ± 5.3 lg/ml in group 2 (stable asthmatic patients) while
the normal control group serum level is 33.9 ± 9.6 lg/ml.
There is also a signiﬁcant difference (P1 < 0.001) between
group 1 and group 2 as regards serum level of sST2 (Fig. 2).Table 2 Serum levels of sST2 in the studied groups.
sST2 (lg/ml) Group 1 Group 2 C
X± SD 96.8 ± 25 83.3 ± 5.3 3
Range 72–95 72–95 1
P1: means probability of difference among the three groups.
P2: means probability of difference between group1 and group2.Table 3 shows that there is a highly signiﬁcant difference
(p1 < 0.001) in serum level of IGE among the three studied
groups with the highest level as 324.7 ± 133.4 IU/ml in group
1 (asthmatic patients during exacerbations) followed by
68.2 ± 47.3 IU/ml in group 2 (stable asthmatic patients) while
the normal control group serum level is 20.6 ± 15.7 IU/ml.
There is also a highly signiﬁcant difference (p1 < 0.001)
between group 1 and group (Fig. 3).
Table 4 shows that there is a highly signiﬁcant difference
(p1 < 0.001) in blood eosinophil percentage among the three
studied groups with the highest level as 324.7 ± 133.4 in group
1 (asthmatic patients during exacerbations) followed by
68.2 ± 47.3 in group 2 (stable asthmatic patients) while the
normal control group percentage is 20.6 ± 15.7. There is also
a highly signiﬁcant a difference (p1 < 0.001) between group 1
and group (Fig. 4).
Table 5 shows that in acute exacerbated patients there is a
signiﬁcant ve correlation between FEV1 and total IgE as (r)
0.427 and p= 0.113. There is also signiﬁcant ve correlation
between FEV1 and IL-33as (r) 0.776 and P= 0.001, while
there is no correlation between FEV1 and sST2.
Table 6 shows that there is a high signiﬁcant +ve corre-
lation between PEFR variability and serum level of sST2 as
(r) +0.524 and p= 0.045, while there is no correlation be-
tween PEFR variability and serum levels of either IgE or
IL-33.ontrol F P1 P1
3.9 ± 9.6 117.625 <0.001 0.012
1.5–45
Table 3 Serum levels of IgE level in the studied groups.
IgE (IU/ml) Group 1 Group 2 Control KW P1 P1
X± SD 324.7 ± 133.4 68.2 ± 47.3 20.6 ± 15.7 41.825 <0.001 <0.001
Median 360 50.7 12.7
Range 145–600 6.8–185.7 5.6–50
X =mean.
KW=Kruskal Wallis test (non parametric test).
P1: means probability of difference among the three groups.
P2: means probability of difference between group1 and group2.
Figure 3 Serum level of IgE (IU/ml) in the studied groups.
Figure 4 Perepheral blood eosinophil % in the studied groups.
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Asthma is a chronic inﬂammatory disease classically character-
ized by airway hyper-responsiveness, allergic inﬂammation,
elevated serum IgE levels and increased Th2 cytokine produc-
tion. Given that IL-33 is a strong inducer of Th2 immune
responses its role in asthma has been extensively studied [6].
IL-33, a member of the IL1-cytokine family, is considered to
be crucial for the induction of T-helper type 2 cell dominant
immune responses such as host defense against nematodes
and allergic diseases [7].
IL-33 receptor was ﬁrst identiﬁed as IL-1 receptor-like mol-
ecule and termed as ST2. ST2 is an Interleukin-1 receptor fam-
ily member and exists in both membranes – bound isoform and
a soluble isoform (sST2) [8]. .
IL-33 is the functional ligand for ST2 and ST2/IL-33 signal-
ing regulating inﬂammation and immunity [9]. IL-33 and its
receptor are part of IL-1 family, and their interactions pro-
mote a variety of actions from a number of different cell types.
The IL-33/ST2 axis is thought to be intimately involved in the
promotion and maintenance of allergic inﬂammation via a
number of cell types that include Th2 cells, mast cells and
basophils, and structural cells such as airway epithelium and
smooth muscle cells [10]. IL-33/ST2 signaling pathway
activates air way eosinophils that exacerbate air way inﬂam-
mation [11].Table 4 Peripheral Blood eosinophil percentage in the studied grou
Eosinophil % Group 1 Group 2
X± SD 16.5 ± 2.6 5.13 ± 2.3
Range (10–21) (2–10)
P1: means probability of difference among the three groups.
P2: means probability of difference between grouop1 and group2.In our study, there was a signiﬁcant rise in serum levels of
both Interlukin-33 and its receptor sST2 in both exacerbated
and stable asthmatic patients and the rise in exacerbated
patients was signiﬁcantly higher than the rise in stable patients
Tables 1 and 2.
Cytokines regulate important biological processes such as
the immune response or hematopoiesis and are involved in
the pathogenesis of many diseases. In the physiological state
their concentrations in biological ﬂuids and tissues are unde-
tectable or very low. Therefore, any increase in their concen-
trations suggests activation of pathways involved in an
inﬂammatory response or disease development. That is why
cytokines may serve as potential biomarkers of various
diseases, and changes of their concentrations may be used in
follow-up. Moreover, the cytokine proﬁle in the acute phase
of the disease often differs from the chronic phase. Measure-
ments of cytokine concentrations are sufﬁcient to diagnose a
disease and their concentrations correlate with the stage of
the disease [12].
In our study, in acute exacerbated patients there was signif-
icant ve correlation between FEV1 and both total IgE and
IL-33 while there was no correlation between FEV1 and serum
level of sST2 (Table 5). In stable asthmatic patients there was
high signiﬁcant +ve correlation between PEFR variability and
serum level of sST2 while there was no correlation betweenps.
Control F P1 P1
1 ± 0.9 354.129 <0.001 <0.001
(0–3)
Table 6 Correlation between PEFR variability and total IgE,
IL-33 and sST2 in group 2 patients.
FEV1
(r) p value
IgE 0.366 0.179
IL-33 0.179 0.522
sST2 +0.524 0.045*
* High signiﬁcant result statistically.
Table 5 Correlation between FEV1 and total IgE, IL-33 and
sST2 in group1 patients.
FEV1
(r) p value
Total IgE 0.427 0.113
IL-33 0.776 0.001
sST2 0.256 0.356
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(Table 6).
IL-33 is increased in Airway smooth muscle and epithelial
cells from asthmatics and this increase positively correlates
with asthma severity [13]. Soluble ST2 is decoy receptor that
is elevated in the serum of asthma patients, soluble ST2 associ-
ation with IL33, blocks ST2L-dependent signaling and the
immunological effect of IL33 [13]. Previous studies reported
that serum ST2 protein levels increased in patients with acute
exacerbation of atopic asthma which is a characteristic of
Th2-mediated eosinophilic airway inﬂammation [14].
Expression of IL-33 was found in higher levels in endotra-
chial biopsies from human asthmatic subjects compared to
controls. IL-33 expression was particularly evident in those
with severe asthma and the expression was mainly located in
bronchial epithelial cells [15].
There are many data suggesting that IL-33 is involved in
lung inﬂammation and support the concept of ST2 as a thera-
peutic target in asthma. Endobronchial biopsies from adults
with mild, moderate, and severe asthma were obtained. Airway
smooth muscle cells (ASMC) from asthmatic samples,
regardless of severity of disease, expressed increased IL-33
mRNA levels compared with controls. IL-33 protein was
predominantly expressed by ASMC and epithelial and endo-
thelial cells in asthmatic lungs but was absent in control sam-
ples. Thus, IL-33 is expressed by ASMC in asthmatic lungs
and shows promise as a potential inﬂammatory marker for
asthma [16].
Soluble ST2 binds to IL-33 and functions as a decoy recep-
tor of IL-33. Pretreatment with soluble ST2 suppressed IL-33
induced NF-kB activity and IL-4, IL-5 and IL-13 expression
[17]. Soluble ST2 has been implicated as an anti-inﬂammatory
mediator in inﬂammatory responses. Pre-treatment with re-
combinant sST2 protein attenuates expression of TNF, IL-6
and IL-12 in macrophages [18]. ST2/IL-33 interactions on mastcells may serve not only to promote maturation and activation,
but also to maintain their localization within the tissue [19].Conclusion
The serum levels of IL-33 and its receptor sST2 were markedly
elevated in patients with bronchial asthma and this supports
the concept of sST2 and Interleukin-33 as a therapeutic target
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